The surge in Acurx Pharmaceuticals' stock price is likely due to the positive results from a Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat. This news has likely increased investor confidence in the company's future prospects, leading to increased demand for the stock and a subsequent rise in its price.